Effects of a new long-acting form of bromocriptine on tumorous hyperprolactinemia
Recently, a new long-acting form of bromocriptine (Parlodel LA, Sandoz) has been developed and it has already been found to be effective in lowering plasma PRL levels in normal volunteers and postpartum women. This work reports the clinical, hormonal and radiological effects of a single 50 mg dose of long-acting bromocriptine in 10 patients with tumorous hyperprolactinemia (2 microprolactinomas, 6 macroprolactinomas, 1 acromegaly and 1 nonsecreting macroadenoma). A rapid and long-lasting (28 days) normalization of PRL levels was observed in patients with microprolactinoma, acromegaly and nonsecreting adenoma. None of the 6 patients with macroprolactinoma underwent normalization of plasma PRL, but the latter was markedly reduced (61–80% of basal levels). A second injection of the drug in 5 macroprolactinoma patients induced a further reduction of plasma PRL levels in 2 of them. No changes in the tumor size were observed either after the first or the second injection of long-acting bromocriptine in any of the patients. This injectable form of bromocriptine induced nausea and/or mild hypotension Jasting a few h in 4 of the 10 patients and was better tolerated than the oral form as regards both the duration and intensity of the side effects. Thus, as this drug has proved to be efficacious and well tolerated by the patients, this long-acting form of bromocriptine may be a valid therapeutical approach for initiating medical treatment of patients with prolactinoma.
Key-wordsTumorous hyperprolactinemia long-acting bromocriptine
Unable to display preview. Download preview PDF.
- 1.Bergh T., Nillius J. Prolactinomas. Follow-up of medical treatment. In: Molinatti G.M. (Ed.), A clinical problem: microprolactinoma. Diagnosis and treatment. Excerpta Medica, Amsterdam, 1982, p. 115.Google Scholar
- 2.Besser G.M., Wass J.A.H., Grossman A., Moult P.J.A., Bouloux P. Hormonal and clinical effects of dopamine agonists. In: Calne D.B. (Eds.), Lisuride and other dopamine agonists. Raven Press, New York, 1983, p. 239.Google Scholar
- 3.Liuzzi A., Chiodini P.G., Oppizzi G., Dallabonzana D., Spelta B., Silvestrini F., Rainer E., Horowski R. Medical treatment of pituitary adenomas: effects on hormonal secretion and tumor size. In: Calne D.B. (Eds.), Lisuride and other dopamine agonists. Raven Press, New York, 1983, p. 231.Google Scholar
- 5.Von Werder K., Eversman T., Fahlbusch R., Müller O.A., Rijosk K. Endocrine-active pituitary adenomas: long-term results of medical and surgical treatment. In: Camanni F., Müller E.E. (Eds.), Pituitary hyperfunction: physiopathology and clinical aspects. Raven Press, New York, 1984, p. 385.Google Scholar
- 6.Wass J.A.H., Besser G.M., Grossman A. The medical management of pituitary tumors. In: Camanni F., Müller E.E. (Eds.), Pituitary hyperfunction: physiopathology and clinical aspects. Raven Press, New York, 1984, p. 407.Google Scholar
- 7.Lancranjan I., Rolland R., L’Hermite M. Inhibition of lactation with depot-bromocriptine. Ann. N. Y. Acad. Sci. (in press).Google Scholar
- 10.Thorner M.O., Schran H.F., Evans W.S., Rogol A.D., Morris J.L., MacLeod R.M. A broad spectrum of PRL suppression by bromocriptine in hyperprolactinemic women: a study of serum prolactin and bromocriptine levels after acute and chronic administration of bromocriptine. J. Clin. Endocrinol. Metab. 50: 1026, 1980.PubMedCrossRefGoogle Scholar
- 11.Spada A., Nicosia S.L., Cortellazzi L.O., Pesso G., Bassetti M., Sartorio A, Giannattasio G. In vitro studies on PRL releasing and adenylate cyclase activity in human prolactin-secreting pituitary adenomas. Different sensitivity of macro and microadenoma to dopamine and vasoactive intestinal polypeptide. J. Clin. Endocrinol. Metab. 56: 1, 1982.CrossRefGoogle Scholar